XML 70 R52.htm IDEA: XBRL DOCUMENT
v3.23.1

Collaboration and License Agreements - Bristol-Myers Squibb Company - Additional Information (Details) $ in Thousands |  |  | 1 Months Ended | 3 Months Ended | 6 Months Ended | 9 Months Ended | 12 Months Ended |  |  |  |  |  |  |
--- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | ---
Apr. 25, 2017 USD ($) Target | Jul. 07, 2014 USD ($) Term Target | Mar. 31, 2020 USD ($) | Jan. 31, 2018 USD ($) | Sep. 30, 2022 USD ($) | Jun. 30, 2022 USD ($) | Mar. 31, 2022 USD ($) | Jun. 30, 2022 USD ($) | Sep. 30, 2022 USD ($) | Dec. 31, 2022 USD ($) | Dec. 31, 2021 USD ($) | Oct. 31, 2022 USD ($) | Dec. 31, 2020 USD ($) | Feb. 29, 2020 USD ($) | Nov. 30, 2017 USD ($) | Mar. 17, 2017 Target | Dec. 31, 2016 USD ($) | Jan. 31, 2016 USD ($)
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Revenue recognized |  |  |  |  | $ 11,147 | $ 12,853 | $ 9,040 | $ 21,893 | $ 33,040 | $ 53,163 | $ 37,312 |  |  |  |  |  |  |
Type of Revenue [Extensible List] |  |  |  |  |  |  |  |  |  | us-gaap:LicenseAndServiceMember | us-gaap:LicenseAndServiceMember |  |  |  |  |  |  |
Deferred revenue |  |  |  |  |  |  |  |  |  | $ 301,326 | $ 284,760 |  | $ 318,707 |  |  |  |  |
Bristol Myers Squibb |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Deferred revenue |  |  |  |  |  |  |  |  |  | $ 169,200 |  |  |  |  |  |  |  |
Collaborative Arrangement | Bristol Myers Squibb |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaboration target research term |  | 2 years |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Number of additional collaboration target | Target |  | 2 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Research terms |  |  |  |  |  |  |  |  |  | Each collaboration target had a two-year research term and the two additional targets had to be nominated by Bristol Myers Squibb within five years of the effective date of the BMS Agreement. The research term for each collaboration target could be extended in one year increments up to three times. |  |  |  |  |  |  |  |
Extension of research term for each collaboration target |  | 1 year |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Upfront payment received | $ 200,000 | $ 50,000 |  |  |  |  |  |  |  | $ 297,000 |  |  |  |  |  |  |  |
Contingent milestone payments receivable |  |  |  |  |  |  |  |  |  |  |  | $ 2,100,000 |  | $ 10,000 |  |  | $ 15,000 | $ 10,000
Number of research targets selected | Target | 8 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Total transaction price |  | 304,700 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Upfront fee received |  | 250,000 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Research and development service fees |  | 17,700 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Milestone payment received |  |  | $ 10,000 | $ 12,000 |  |  |  |  |  |  |  |  |  |  |  |  |  |
Milestone payments received |  |  |  |  |  |  |  |  |  | 297,000 |  |  |  |  |  |  |  |
Deferred revenue |  |  |  |  |  |  |  |  |  | $ 169,200 | $ 178,300 |  |  |  |  |  |  |
Collaborative Arrangement | Bristol Myers Squibb | Pre Clinical Candidate |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Contingent milestone payments receivable |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | $ 2,000 |
Collaborative Arrangement | Bristol Myers Squibb | Third And Fourth Target |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Target selection fee |  | $ 25,000 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaborative Arrangement | Bristol Myers Squibb | New Drug Application for CTLA-4 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Contingent milestone payments receivable |  |  |  |  |  |  |  |  |  |  |  |  |  |  | $ 10,000 |  |  |
Collaborative Arrangement | Maximum | Bristol Myers Squibb |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Number of oncology target | Target |  | 4 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Number of collaboration target | Target |  | 2 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Period of nomination of additional target from effective date |  | 5 years |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Times of increments for extended collaboration target research time | Term |  | 3 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaborative Arrangement | Maximum | Bristol Myers Squibb | Each Of Two Additional Targets |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Contingent milestone payments receivable |  | $ 25,000 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaboration and License Agreement | Maximum | Bristol Myers Squibb |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Number of additional collaboration target | Target |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 8 |  |

X
- Definition Aggregate collaboration transaction amount. + References No definition available. + Details
Name: | ctmx_AggregateCollaborationTransactionAmount
Namespace Prefix: | ctmx_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Collaboration target research term. + References No definition available. + Details
Name: | ctmx_CollaborationTargetResearchTerm
Namespace Prefix: | ctmx_
Data Type: | xbrli:durationItemType
Balance Type: | na
Period Type: | duration

X
- Definition Future contingent milestone payment receivable. + References No definition available. + Details
Name: | ctmx_ContingentMilestonePaymentsReceivable
Namespace Prefix: | ctmx_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition Extension of research term for each collaboration target. + References No definition available. + Details
Name: | ctmx_ExtensionOfResearchTermForEachCollaborationTarget
Namespace Prefix: | ctmx_
Data Type: | xbrli:durationItemType
Balance Type: | na
Period Type: | duration

X
- Definition Increments of extended collaboration target research times. + References No definition available. + Details
Name: | ctmx_IncrementsOfExtendedCollaborationTargetResearchTimes
Namespace Prefix: | ctmx_
Data Type: | xbrli:integerItemType
Balance Type: | na
Period Type: | instant

X
- Definition Milestone payment received. + References No definition available. + Details
Name: | ctmx_MilestonePaymentReceived
Namespace Prefix: | ctmx_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Milestone payments received from revenue recognized during period. + References No definition available. + Details
Name: | ctmx_MilestonePaymentsReceivedFromRevenueRecognizedDuringPeriod
Namespace Prefix: | ctmx_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Number of additional collaboration target. + References No definition available. + Details
Name: | ctmx_NumberOfAdditionalCollaborationTarget
Namespace Prefix: | ctmx_
Data Type: | xbrli:integerItemType
Balance Type: | na
Period Type: | instant

X
- Definition Number of collaboration target. + References No definition available. + Details
Name: | ctmx_NumberOfCollaborationTarget
Namespace Prefix: | ctmx_
Data Type: | xbrli:integerItemType
Balance Type: | na
Period Type: | instant

X
- Definition Number of oncology target. + References No definition available. + Details
Name: | ctmx_NumberOfOncologyTarget
Namespace Prefix: | ctmx_
Data Type: | xbrli:integerItemType
Balance Type: | na
Period Type: | instant

X
- Definition Number of research targets selected. + References No definition available. + Details
Name: | ctmx_NumberOfResearchTargetsSelected
Namespace Prefix: | ctmx_
Data Type: | xbrli:integerItemType
Balance Type: | na
Period Type: | instant

X
- Definition Period of nomination of additional target. + References No definition available. + Details
Name: | ctmx_PeriodOfNominationOfAdditionalTarget
Namespace Prefix: | ctmx_
Data Type: | xbrli:durationItemType
Balance Type: | na
Period Type: | duration

X
- Definition Research and development service fees. + References No definition available. + Details
Name: | ctmx_ResearchAndDevelopmentServiceFees
Namespace Prefix: | ctmx_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Target selection fees. + References No definition available. + Details
Name: | ctmx_TargetSelectionFees
Namespace Prefix: | ctmx_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Upfront fee received. + References No definition available. + Details
Name: | ctmx_UpfrontFeeReceived
Namespace Prefix: | ctmx_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + References No definition available. + Details
Name: | us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 606 -SubTopic 10 -Section 45 -Paragraph 1 -URI https://asc.fasb.org/extlink&oid=126919976&loc=SL49130531-203044 Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 606 -SubTopic 10 -Section 50 -Paragraph 8 -Subparagraph (a) -URI https://asc.fasb.org/extlink&oid=126920106&loc=SL49130549-203045 Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 606 -SubTopic 10 -Section 45 -Paragraph 2 -URI https://asc.fasb.org/extlink&oid=126919976&loc=SL49130532-203044 + Details
Name: | us-gaap_ContractWithCustomerLiability
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Cash received from collaborators during the current period. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 25 -Subparagraph (a) -URI https://asc.fasb.org/extlink&oid=126954810&loc=d3e3536-108585 + Details
Name: | us-gaap_ProceedsFromCollaborators
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Describes the terms of significant agreements under research and development arrangements accounted for as a contract to perform research and development for others (including royalty arrangements, purchase provisions, license agreements, and commitments to provide additional funding), aggregated by similar arrangements or individually if necessary to understand the effects on the financial statements. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 730 -SubTopic 20 -Section 50 -Paragraph 1 -Subparagraph (a) -URI https://asc.fasb.org/extlink&oid=6420387&loc=d3e23199-108380 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 730 -SubTopic 20 -Section 50 -Paragraph 3 -URI https://asc.fasb.org/extlink&oid=6420387&loc=d3e23221-108380 + Details
Name: | us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersDescriptionAndTerms
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 30 -Subparagraph (a) -URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599 Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 40 -URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e9031-108599 Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 41 -Subparagraph (a) -URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e9038-108599 Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 32 -Subparagraph (b) -URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599 Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 32 -Subparagraph (a) -URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599 Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 606 -SubTopic 10 -Section 50 -Paragraph 4 -Subparagraph (a) -URI https://asc.fasb.org/extlink&oid=126920106&loc=SL49130543-203045 Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 22 -Subparagraph (b) -URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599 Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 22 -Subparagraph (a) -URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599 Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 42 -URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e9054-108599 Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 606 -SubTopic 10 -Section 50 -Paragraph 5 -URI https://asc.fasb.org/extlink&oid=126920106&loc=SL49130545-203045 Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 924 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SAB Topic 11.L) -URI https://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856 + Details
Name: | us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Indicates type of revenue from product and service. Includes, but is not limited to, revenue from contract with customer and other sources. + References No definition available. + Details
Name: | us-gaap_TypeOfRevenueExtensibleList
Namespace Prefix: | us-gaap_
Data Type: | enum2:enumerationSetItemType
Balance Type: | na
Period Type: | duration

X
- Details
Name: | srt_CounterpartyNameAxis=ctmx_BristolMyersSquibbCompanyMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=us-gaap_CollaborativeArrangementMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=ctmx_PreClinicalCandidateMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=ctmx_ThirdAndFourthTargetsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=ctmx_DrugApplicationForCTLA4Member
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_RangeAxis=srt_MaximumMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_ContingentConsiderationByTypeAxis=ctmx_AchievingAdditionalTargetsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=ctmx_CollaborationAndLicenseAgreementMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |